MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones

5/22/24 8:08:34 AM ET

$LEGN

$MXCT

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $LEGN alert in real time by email

MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones

Get the next $LEGN alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$LEGN
$MXCT

Company	Date	Price Target	Rating	Analyst
Legend Biotech Corporation $LEGN	2/12/2026	$24.00	Buy → Neutral	Rothschild & Co Redburn
Legend Biotech Corporation $LEGN	1/22/2026	$21.00	Buy → Hold	TD Cowen
Legend Biotech Corporation $LEGN	1/7/2026	$75.00	Outperform	Oppenheimer
Legend Biotech Corporation $LEGN	10/7/2025	$40.00	Overweight	Cantor Fitzgerald
MaxCyte Inc. $MXCT	8/11/2025		Buy → Neutral	BTIG Research
MaxCyte Inc. $MXCT	8/7/2025		Outperform → Mkt Perform	William Blair
MaxCyte Inc. $MXCT	7/22/2025	$6.00	Overweight	Stephens
Legend Biotech Corporation $LEGN	10/8/2024	$86.00	Buy	Redburn Atlantic

More analyst ratings

MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$LEGN
$MXCT

MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$LEGN
$MXCT

$LEGN
$MXCT
Analyst Ratings

Legend Biotech downgraded by Rothschild & Co Redburn with a new price target

Legend Biotech downgraded by TD Cowen with a new price target

Oppenheimer initiated coverage on Legend Biotech with a new price target

$LEGN
$MXCT
Press Releases

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

$LEGN
$MXCT
Insider Trading

SEC Form 4 filed by Huang Ying

SEC Form 4 filed by Swirsky Douglas J

SEC Form 3 filed by new insider Heyman Tomas J.

$LEGN
$MXCT
Insider Purchases

CHIEF FINANCIAL OFFICER Swirsky Douglas J bought $64,500 worth of shares (50,000 units at $1.29), increasing direct ownership by 45% to 161,811 units (SEC Form 4)

President and CEO Masoud Maher bought $102,915 worth of shares (75,000 units at $1.37), increasing direct ownership by 75% to 175,000 units (SEC Form 4)

Director Erck Stanley C bought $137,220 worth of shares (100,000 units at $1.37), increasing direct ownership by 34% to 398,328 units (SEC Form 4)

$LEGN
$MXCT
SEC Filings

MaxCyte Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by MaxCyte Inc.

SEC Form 144 filed by Legend Biotech Corporation

$LEGN
$MXCT
Leadership Updates

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

Legend Biotech Appoints Carlos Santos as Chief Financial Officer

$LEGN
$MXCT
Financials

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

$LEGN
$MXCT
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

Amendment: SEC Form SC 13G/A filed by MaxCyte Inc.

Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $LEGN$MXCT

MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $LEGN$MXCT

$LEGN$MXCT Analyst Ratings

Legend Biotech downgraded by Rothschild & Co Redburn with a new price target

Legend Biotech downgraded by TD Cowen with a new price target

Oppenheimer initiated coverage on Legend Biotech with a new price target

$LEGN$MXCT Press Releases

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

$LEGN$MXCT Insider Trading

SEC Form 4 filed by Huang Ying

SEC Form 4 filed by Swirsky Douglas J

SEC Form 3 filed by new insider Heyman Tomas J.

$LEGN$MXCT Insider Purchases

CHIEF FINANCIAL OFFICER Swirsky Douglas J bought $64,500 worth of shares (50,000 units at $1.29), increasing direct ownership by 45% to 161,811 units (SEC Form 4)

President and CEO Masoud Maher bought $102,915 worth of shares (75,000 units at $1.37), increasing direct ownership by 75% to 175,000 units (SEC Form 4)

Director Erck Stanley C bought $137,220 worth of shares (100,000 units at $1.37), increasing direct ownership by 34% to 398,328 units (SEC Form 4)

$LEGN$MXCT SEC Filings

MaxCyte Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by MaxCyte Inc.

SEC Form 144 filed by Legend Biotech Corporation

$LEGN$MXCT Leadership Updates

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

Legend Biotech Appoints Carlos Santos as Chief Financial Officer

$LEGN$MXCT Financials

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

$LEGN$MXCT Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

Amendment: SEC Form SC 13G/A filed by MaxCyte Inc.

Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

Recent Analyst Ratings for
$LEGN
$MXCT

Recent Analyst Ratings for
$LEGN
$MXCT

$LEGN
$MXCT
Analyst Ratings

$LEGN
$MXCT
Press Releases

$LEGN
$MXCT
Insider Trading

$LEGN
$MXCT
Insider Purchases

$LEGN
$MXCT
SEC Filings

$LEGN
$MXCT
Leadership Updates

$LEGN
$MXCT
Financials

$LEGN
$MXCT
Large Ownership Changes